Technical Report Pharmaceutical Patents and Generic Entry Competition: A New View on the Hatch-Waxman Act

MIYAGIWA, Kaz  ,  WAN, Jiangyun(Yunyun)

2016-07 , Institute of Innovation Research, Hitotsubashi University
Description
Revised on July 11, 2016
We present a formal analysis that sheds new light on the Hatch-Waxman Act. Hatch-Waxman restores incentives to develop new drugs by extending the patent life for them, but also promotes generic entry by reducing entry costs and by providing 180-day marketing exclusivity to a first challenger to the patent. Although these two objectives appear incompatible, our model shows that marketing exclusivity, with a significant entry cost reduction, contributes to incentive restoration. It finds however that social welfare is lower with marketing exclusivity. Finally, our analysis suggests that marketing exclusivity not be granted in the case of drugs for rare diseases.
Full-Text

http://hermes-ir.lib.hit-u.ac.jp/rs/bitstream/10086/28105/1/070iirWP15-18.pdf

Number of accesses :  

Other information